Halozyme Therapeutics (HALO)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.48 (+0.98%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Halozyme Therapeutics (HALO)
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Key Insights

Critical company metrics and information
  • Share Price

    $49.60
  • Market Cap

    $6.31 Billion
  • Total Outstanding Shares

    127.23 Million Shares
  • Total Employees

    373
  • Dividend

    No dividend
  • IPO Date

    March 12, 2004
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Homepage

    https://www.halozyme.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities, Continuing$-222.37 Million
Net Cash Flow From Investing Activities$-300.49 Million
Net Cash Flow, Continuing$-119.91 Million
Net Cash Flow From Financing Activities$-222.37 Million
Net Cash Flow From Operating Activities$402.95 Million
Net Cash Flow From Operating Activities, Continuing$402.95 Million
Net Cash Flow$-119.91 Million
Net Cash Flow From Investing Activities, Continuing$-300.49 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Costs And Expenses$470.35 Million
Gross Profit$777.70 Million
Net Income/Loss$392.47 Million
Basic Earnings Per Share$3.07
Preferred Stock Dividends And Other Adjustments$0.00
Income/Loss From Continuing Operations Before Tax$480.09 Million
Operating Income/Loss$477.01 Million
Basic Average Shares$252.91 Million
Income Tax Expense/Benefit$87.63 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Operating Expenses$300.69 Million
Diluted Average Shares$258.19 Million
Net Income/Loss Available To Common Stockholders, Basic$392.47 Million
Diluted Earnings Per Share$3.02
Research and Development$79.94 Million
Net Income/Loss Attributable To Parent$392.47 Million
Other Operating Expenses$71.05 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Benefits Costs and Expenses$467.26 Million
Cost Of Revenue$169.66 Million
Revenues$947.36 Million
Income/Loss From Continuing Operations After Tax$392.47 Million
Selling, General, and Administrative Expenses$149.69 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Fixed Assets$39.98 Million
Other Non-current Liabilities$52.36 Million
Inventory$131.41 Million
Current Liabilities$108.81 Million
Noncurrent Assets$991.05 Million
Liabilities And Equity$2.12 Billion
Prepaid Expenses$31.05 Million
Long-term Debt$1.50 Billion
Other Current Assets$964.51 Million
Other Non-current Assets$531.49 Million
Equity$452.70 Million
Current Assets$1.13 Billion
Equity Attributable To Parent$452.70 Million
Accounts Payable$12.40 Million
Other Current Liabilities$96.42 Million
Liabilities$1.67 Billion
Equity Attributable To Noncontrolling Interest$0.00
Intangible Assets$419.59 Million
Noncurrent Liabilities$1.56 Billion
Assets$2.12 Billion

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.